| name | endo-hirsutism-start-pharmacologic-therapy-patient-important |
| description | Initiates oral contraceptives or other pharmacologic agents as first‑line treatment for women with hirsutism that causes sufficient distress to seek additional treatment despite shaving, plucking, or waxing. Trigger phrase: "She’s tried shaving and waxing but still wants treatment; should we start medicine?" |
Start pharmacologic therapy for patient‑important hirsutism despite cosmetic measures
STEP 1 — Gather Information
Collect menstrual history, hirsutism severity (patient‑important distress), cosmetic methods tried (shaving, plucking, waxing), desire for additional cosmetic benefit, fertility intentions, contraception use, BMI, age, signs of hyperandrogenism (acne, alopecia), and VTE risk factors (obesity, age >39).
STEP 2 — Rule In / Rule Out
Is the hirsutism patient‑important despite cosmetic measures? If yes, proceed to pharmacologic therapy; if no (mild hirsutism, no distress, no desire for additional treatment), consider either pharmacologic therapy or direct hair removal or no treatment.
STEP 3 — Classify or Stratify
Stratify by VTE risk (obesity or age >39) → choose low‑dose EE OC; by fertility desire (seeking pregnancy) → avoid antiandrogens unless reliable contraception; by desire for added cosmetic benefit after OC → plan to add direct hair removal if needed; by mild hirsutism without endocrine disorder → either pharmacologic therapy or direct hair removal is acceptable.
STEP 4 — Decide
Start combined oral estrogen–progestin contraceptive as first‑line; reassess after ≥6 months; if suboptimal, add an antiandrogen; if additional cosmetic benefit desired, add direct hair removal; for high VTE risk, use EE ≤20 mcg with low‑risk progestin; if not seeking pregnancy and adequate contraception, antiandrogen monotherapy may be considered; otherwise avoid antiandrogen monotherapy.
Clinical Guardrails / Mimics / Pitfalls
Do not start antiandrogen monotherapy without reliable contraception due to teratogenic risk; do not use insulin‑lowering drugs solely for hirsutism; avoid flutamide because of hepatotoxicity; avoid topical antiandrogens; avoid GnRH agonists except in severe hyperandrogenemia with suboptimal response to OC/antiandrogen; do not initiate OC+antiandrogen combination as routine first‑line; ensure a minimum 6‑month trial before changing dose or adding medication.
Concrete Clinical Example
A 30‑year‑old woman with PCOS reports facial hirsutism causing distress despite daily shaving and weekly waxing; she has regular menses, desires no pregnancy, BMI 24, age <39. Start an OC containing EE 20 mcg and norgestimate 0.25 mg; schedule follow‑up in 6 months to assess response and consider adding spironolactone if needed.
Source: Evaluation and Treatment of Hirsutism in Premenopausal Women: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2018, DOI:10.1210/jc.2018-00241
